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A B S T R A C T
Purpose: Clear cell Renal Cell Carcinomas (ccRCC), the largest group of renal tumours, are resistant to classical
therapies. The determination of the functional state of actionable biomarkers for the assessment of these ade-
nocarcinomas is essential. The dysregulation of the oncoprotein, PKB/Akt has been linked with poor prognoses
in human cancers.
Material & methods: We analysed the status of the PKB/Akt pathway in a representative tumour tissue microarray
obtained from the primary tumours and their metastases in 60 ccRCC with long term follow up. We sought to
deﬁne the evolution of this pathway from the primary tumour to the metastatic event and to know the impact of
its functional state in tumour aggressiveness and patient survival. Two-site time resolved ampliﬁed FRET (A-
FRET) was utilised for assessing the activation state of PKB/Akt and this was compared to conventional im-
munohistochemistry measurements.
Results: Activation state of PKB/Akt in primary tumours deﬁned by A-FRET correlated with poorer overall
survival (hazard ratio 0.228; p= 0.002). Whereas, increased protein expression of phosphoPKB/Akt, identiﬁed
using classical immunohistochemistry, yielded no signiﬁcant diﬀerence (hazard ratio 1.390; p= 0.548).
Conclusions: Quantitative determination of PKB/Akt activation in ccRCC primary tumours alongside other di-
agnostics tools could prove key in taking oncologists closer to an eﬃcient personalised therapy in ccRCC pa-
tients.
General signiﬁcance: The quantitative imaging technology based on Ampliﬁed-FRET can rapidly analyse protein
activation states and molecular interactions. It could be used for prognosis and assess drug function during the
early cycles of chemotherapy. It enables evaluation of clinical eﬃciency of personalised cancer treatment.
1. Introduction
Clear cell renal cell carcinomas (ccRCCs) are a major health concern
in the West as they are quite a common aggressive radio- and chemo-
resistant neoplasm [1]. Only surgery has demonstrated a signiﬁcant
impact in patient survival, the 5-year overall mortality of this neoplasm
is still reaching around 40% [2]. Truncal mutations in the Von Hip-
pel–Lindau VHL tumour suppressor gene are the hallmark of this pa-
thology, but therapies against this target have elicited, to date, only
partial responses. These disappointing results are mainly related to the
inherent high intratumoral heterogeneity (ITH) that ccRCCs display to
the point that ITH is nowadays a major obstacle to the implementation
of eﬃcient therapies impacting signiﬁcantly on patient survival [3].
The aim of this study is to determine whether the phosphoinositide
3-kinase (PI3K)/protein kinase B (PKB/Akt) dysregulation is implicated
in the mechanisms underlying ccRCC carcinogenesis and its hypothe-
tical impact on patient survival. To pursue this investigation a recently
developed approach was utilised to determine the functional status of
the PKB/Akt signalling pathway [4].
Protein kinase B (PKB/Akt) is a kinase from the AGC kinase
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superfamily which promotes cell growth, survival and proliferation
[5,6]. Upon the binding of a growth factor receptor to a receptor tyr-
osine kinase, phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) is
phosphorylated, by phosphoinositide 3-kinase (PI3K) to phosphatidy-
linositol 3,4,5-triphosphate (PtdIns(3,4,5)P3). This transient formation
of PtdIns(3,4,5)P3 recruits PKB and phosphoinositide-dependent pro-
tein kinase 1 (PDK1) to the plasma membrane. Upon the change in
conformation of PKB, PDK1 phosphorylates threonine-308 to partially
active it [7,8]. Full activation is achieved by m-TOR in complex 2 which
phosphorylates serine 473 [9]. An overview of the PKB signalling
pathway is shown in Fig. 1. PKB is known to be dysregulated in many
human cancer [5]. This dysregulation can occur via the loss of inhibi-
tion through phosphatase and tensin homolog (PTEN) for example, or
through the upregulation of the PI3K-Akt pathway [6,10,11]. Alter-
natively, a mutation of PKB itself could cause dysregulation within this
pathway [12].
Currently, the use of ﬂuorescent microscopy to detect protein ex-
pression is based on measuring the intensity and therefore proves to be
imprecise; as well as lacking a dynamic range for providing a detailed
view on the activation state of oncoproteins in the diagnosis and
prognosis of various cancers. Assessing the expression levels of proteins
does not provide information on the activation states of the protein in
the advancement of a cancer. This is important as expression levels and
activation states of oncoproteins do not necessarily correlate [4,13].
Our method uses ampliﬁed Förster Resonance Energy Transfer (FRET),
detected by a multiple frequency domain ﬂuorescent lifetime imaging
microscopy (mf FLIM), to assess the activation of diﬀerent oncoproteins
in primary and metastatic tumours of the same patients. It has been
previously shown that this method, when used to assess PKB activation
in breast tumours, correlated a higher PKB activation with a worse
prognosis [4].
The principles of FRET involve the non-radiative transfer of energy
from one chromophore to another via dipole-dipole interactions at a
distance equal to or< 10 nm. An appropriately selected donor chro-
mophore must have an emission spectrum that overlaps with the ex-
citation spectrum of the chosen acceptor chromophore. When excited in
the presence of an acceptor, the lifetime of a donor is decreased due to
the depopulation of its excited state, where its energy is non-radiatively
transferred to the acceptor chromophore [14]. The ﬂuorescent labelling
of PKB on both serine and threonine sites will experience FRET upon
the increase in the activation state of PKB/Akt.
Exploiting this quantitative methodology has enabled us to show
that the PKB/Akt activation in ccRCC primary tumours alongside other
diagnostics tools could prove key in taking oncologists closer to an ef-
ﬁcient personalised therapy in ccRCC patients.
2. Materials and methods
The authors declare that all the experiments carried out in this study
comply with current Spanish and European Union legal regulations.
Samples and data from patients included in this study were obtained
from the medical records and archives of the Pathology Lab (Cruces
University Hospital). All patients were informed about the potential use
for research of their surgically resected tissues, and accepted this
Fig. 1. Schematic overview of the Protein Kinase B signalling pathway.
Protein Kinase B (PKB/Akt) is part of the AGC kinase super family. Upon the binding of a growth factor receptor to a receptor tyrosine kinase, phosphatidylinositol 4,5-bisphosphate
(PtdIns(4,5)P2) is phosphorylated, by phosphoinositide 3-kinase (PI3K) to phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3). This recruits PKB and phosphoinositide-dependent
protein kinase 1 (PDK1) to the plasma membrane. PDK1 phosphorylates threonine-308 to partially active it and mTORC2 phosphorylates Ser473 for full activation.
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eventuality by signing a speciﬁc document. This study was approved by
the Ethical and Scientiﬁc Committee (CEIC-Euskadi PI2015060).
2.1. Patient samples
Two experienced uropathologists (RG, JIL) performed the patholo-
gical analysis, re-assigned grade and stage to all tumours and selected
the appropriate tumour areas for analysis, including them in tumour
microarrays (TMAs). The International Society of Urological Pathology
(ISUP) 2013 tumour grading system [15] was assigned to every sample
in the TMA on routine haematoxylin and eosin sections. Grade was
grouped as low (G1/2) and high (G3/4) for higher consistency. UICC
2010 tumour staging system [16] was assigned to every case at the time
of pathological diagnoses on nephrectomy specimens. Staging was
grouped as pT1/2 (tumours conﬁned to the kidney) and pT3 (tumours
invading outside the kidney).
2.2. TMA preparation
In every case, well preserved tumour areas of the highest grade,
both in the primary tumour and its metastasis, were selected for ana-
lysis. Samples of 2.5 mm in diameter of these areas were obtained from
the paraﬃn blocks and placed randomly in TMAs in a routine way to
ensure a blind evaluation. Internal controls were included in all TMAs.
Unstained 4 μm-thick samples of TMAs were mounted on slides ready
for FRET analysis.
2.3. Antibodies and reagents
Monoclonal antibodies, rabbit anti-pAkt and mouse anti-panAkt
were purchased from Cell Signalling Technology. Pierce endogenous
peroxidase suppressor was also obtained from Thermo Fisher Scientiﬁc
(catalogue no. 35000). AﬃniPure F(ab′)2 fragment donkey anti-rabbit
IgG and peroxidase-conjugated AﬃniPure F(ab′)2 fragment donkey
anti-rabbit IgG were purchased from Jackson Immuno Research
Laboratories. ATTO 488 NHS ester was purchased and was conjugated
to the AﬃniPure F(ab′)2 IgG as described in [4]. Prolong diamond anti-
fade mount (catalogue no. P36970), bovine serum albumin (BSA)
blocking reagent, ampliﬁcation buﬀer and tyramide were all obtained
from Life Technologies (catalogue nos. T20915COMPONENT - D, E and
A).
2.4. Förster resonance energy transfer (FRET) by ﬂuorescence lifetime
imaging microscopy (FLIM)
2.4.1. Two-site ampliﬁed FRET assay for PKB/Akt activation quantiﬁcation
The slides underwent de-waxing and rehydration followed by heat
antigen retrieval in Tris-EDTA (pH 9.0) buﬀer. Slides were incubated
with peroxidase suppressor for 30 min. Afterwards slides were in-
cubated for 1 h with fresh 1% (10 mg/ml) BSA blocking buﬀer.
Following this the slides were incubated overnight at 4 °C with the
primary antibodies (pan-Akt 1:50, p-Akt 1:100). For secondary anti-
body labelling, donor only slides were incubated with Fab-ATTO488
(1:100) and donor acceptor slides with Fab-ATTO488 (1:100) and Fab-
HRP (1:200) for 2 h at room temperature. Tyramide signal ampliﬁca-
tion was carried out on donor/acceptor slides. Fab-HRP is bound to the
primary acceptor antibodies. Tyramide which is conjugated to
Alexa594 is then added which, in the presence of H2O2, leads to the
binding of the Alexa594 chromophore to the HRP molecule, thus
ﬂuorescently labelling the acceptor site. Slides were mounted with
Prolong Diamond anti-fade mount.
2.4.2. Analysis of biomarker activation using multiple frequency domain
FLIM
Immunohistochemistry (IHC) and immunoﬂuorescence (IF) both
operate around a one-site assay whereas A-FRET employs the use of a
two-site assay. A one-site assay detects only one antigen site at a time
and induces non-speciﬁcity. A two-site assay detects two antigen sites
simultaneously hence rendering an augmented precision. The con-
jugation of the chromophores to Fab fragments, which bind to the two
primary antibodies, allowed the critical FRET distance of 10 nm or less
to be kept and provided a suitable tool for measuring the activation
state of a given biomarker. To detect the signal of a sample with good
precision and overcome autoﬂuorescence, especially in ﬁxed tissue
samples, a signal to noise ratio of at least 4-fold must be observed. To
achieve this, tyramide signal ampliﬁcation was carried out.
Using a high throughput mfFLIM (FASTBASE SOLUTIONS Ltd. and
Lambert Instruments), a mapping ﬁle was created semi-automatically
which mapped each tumour core according to its position on the slide.
Mapping the whole tumour core allowed each sample to be analysed
completely rather than using segmental analysis. Images and results
were automatically acquired from the arrays according to their posi-
tioning. Phase, lifetimes and average intensities were all calculated
automatically and saved as an excel ﬁle, as well as lifetime images.
2.5. Statistical analysis
Statistical analysis was performed using the GraphPad Prism soft-
ware to create Kaplan-Meier survival curves and Origin Pro8 used to
provide statistical analysis and generate box and whisker plots.
Statistical diﬀerences were calculated between groups using the Mann-
Whitney U test (values indicated within the box and whisker plots). The
Mann-Whitney U test is a nonparametric test which does not assume a
normal distribution of results. P values ≤0.05 indicated a statistical
diﬀerence from the null hypothesis. Box and whisker plots represent the
25–75% range (box) and the 1–99 range (whiskers). Statistical diﬀer-
ences are indicated with p values ≤0.05. For Kaplan-Meier survival
curves, overall survival was plotted, which calculated a patient's time
from diagnosis until death or until the patient was last seen. The hazard
ratio was also calculated for each Kaplan-Meier curve. Multivariate
analysis was also performed to exclude inﬂuences among the evaluated
parameters. A non-parametric Mann-Whitney U test was also used to
see if there was correlation between diﬀerent parameters and FRET
eﬃciency or intensity and plotted as a Mann-Whitney plot.
3. Results
3.1. Patient data
The series includes 60 patients diagnosed, treated and followed in
the Cruces University Hospital from 1990 to 2014. Males predominated
in the series (46 M/14F) with an average age of 58.5 years (range
25–83). Primary tumours were located in the right kidney in 29 cases
and in the left kidney in 31 cases. The average tumour diameter was
8.5 cm (range 2–19). Thirty-two primary tumours were organ conﬁned
(pT1 and pT2) at the time of diagnosis. Twenty-ﬁve cases were low
grade tumours (grades G1/2) and 35 were high grade (grades G3/4). At
the time when the follow-up was closed (Dec 2015), 40 (66.6%) pa-
tients had died of disease. The average clinical follow up was
67.5 months (range 1–240). The elapsed time between the diagnosis of
the primary tumour and the metastasis widely oscillated, from 0 to
204 months. Epithelial organs, mostly lung and pancreas, were the sites
of the metastatic seed in 29 cases (48.3%), lymph nodes in 13 cases
(21.6%) and soft tissues/bone in 18 cases (30%).
Fig. 2A shows haematoxylin and eosin staining's for typical low (left
hand panel) and high (right hand panel) grade ccRCC samples. ISUP
grading system [7] was assigned to every sample in the TMA. Samples
were grouped as low (G1/2) and high (G3/4) grades for higher con-
sistency. Fig. 2B shows ﬂuorescent intensity maps and lifetime maps for
the primary (left hand panel) and metastatic (right hand panel) tumour
samples of one patient. The two-site assay was used to label pan Akt and
pThr308-Akt simultaneously for each patient sample. The donor and
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acceptor intensity images indicate PKB/Akt and pThr308-Akt expres-
sion levels respectively. These images were equivalent to IHC images
where little diﬀerence was observed between the primary and meta-
static samples. Conversely, in the lifetime maps, a clear diﬀerence was
observed between the samples, where lower lifetimes (see pseudo-
colour scale) were indicative of higher PKB/Akt activation state. Some
diﬀerence in ﬂuorescence lifetime can be observed between the donor
only samples of the primary and metastatic tumours of each patient
however comparisons should be made between the donor and donor/
acceptor of the same patient. Fig. 2C shows the primary and metastatic
PKB/Akt activation state for all patients determined by A-FRET. Some
patients, such as patient 56, had a negligible PKB/Akt activation state
in the primary tumour FRET Eﬃciency (Ef) = 0%. However, the FRET
eﬃciency increased to 44.2% in the equivalent metastatic tumour.
Thus, a low activation state of PKB/Akt did not necessarily correlate
with an equivalent activation state in its corresponding metastatic
Fig. 2. PKB/Akt activation is higher in metastatic ccRCC tumours in FFPE TMAs.
A, Low-(left) and high-(right) grade ccRCCs B, the intensity images (corresponding to protein expression levels) of PKB/Akt and pAkt expression levels do not yield diﬀerences. Lifetime
maps however do yield signiﬁcant diﬀerences between primary and metastatic ccRCC samples. C, PKB/Akt activation state determined by A-FRET from primary to metastatic tumours for
each patient. Patients 9 and 31 have higher Akt activation in their primary tumours D, the Box and Whisker plots show an increase in PKB/Akt activation from the non-tumour control
tissue to the primary ccRCC cores with a signiﬁcant diﬀerence of (p= 3.81 × 10−5). Each point on the Box and Whisker plot indicates the activation state of the primary and metastatic
tumours of each patient. A larger increase in activation is shown from primary cores to metastatic cores. P values are shown between signiﬁcantly diﬀerent groups.
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evolution. Fig. 2D shows the Ef of diﬀerent patients plotted as Box and
Whiskers distributions. The median Ef diﬀerences between primary and
metastatic tumour samples were compared to noncancerous renal
control tissue. The non-parametric Mann-Witney U statistical tests il-
lustrate a signiﬁcant diﬀerence between the median of the Box and
Whiskers plots of primary and metastatic tumours (p= 3.81 × 10−5)
and between metastatic and noncancerous control tissue
(p= 3.83 × 10−7). The Ef parameter was utilised as a variable to as-
sess patient prognosis. The highest 25% and lowest 75% Ef values were
used to plot the Kaplan-Meier survival curves. Fig. 3A shows that PKB/
Akt activation state correlated with a poorer clinical outcome. The
patients with the highest 25% of PKB/Akt activation were shown to
have poorer prognoses when compared to the lower 75% (n= 16,
p= 0.0018, HR = 0.22279 with 95% CI, 0.052–1.005). When using
intensity and protein expression as a method of analysis, a signiﬁcant
diﬀerence was not observed between the groups (n = 16, p= 0.5483,
HR = 1.3912 with 95% CI, 0.484–4.000). Fig. 3B and C summarise
Mann-Whitney U tests performed on the primary ccRCC tumours. These
statistical analyses determined the correlations between Ef or IHC
methods (pThr308-Akt-acceptor intensity) with histological grading
(low (G1/2) and high (G3/4) grades) and staging (pT1/2 or pT3 in
primary tumours). Neither A-FRET nor intensity determinations
showed signiﬁcant correlations with tumour grading or staging (con-
ﬁned versus not conﬁned).
Fig. 3. PKB/Akt activation state correlates with poor overall survival in ccRCC.
A, shows the survival outcomes related to PKB/Akt activation as determined by A-FRET (left panel) or by conventional IHC (right panel). A highly signiﬁcant diﬀerence was observed
between the upper quartile of FRET Eﬃciency and the lower 3 quartiles FRET Eﬃciency. No diﬀerence was detected when survival is determined by IHC intensity of the activation state of
PKB/Akt. B, Both A-FRET and IHC detections did not relate to grading (High H and Low L) p= 0.709 and p= 0.968. C, A-FRET and IHC measurements did not show signiﬁcant
correlations between staging (conﬁned, c, versus non-conﬁned, n, primary tumours) p= 0.774 and p= 0.065 respectively.
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4. Discussion
PKB/Akt is an oncoprotein, which is dysregulated in many human
cancers [5]. Recently we have shown that its activation state is corre-
lated to poor prognosis in breast cancer patients [4]. We also demon-
strated that expression levels and activation states of oncoproteins did
not necessarily correlate [4]. We therefore sought to assess whether in
ccRCC patients, where the tyrosine kinase receptor pathways are dys-
regulated, PKB/Akt activation states would identify a worse clinical
outcome. To validate this assessment, we constructed formalin-ﬁxed
paraﬃn embedded (FFPE) TMAs that included representative samples
both of primary tumours and their metastases, either synchronic or
metachronic, of 60 ccRCC patients with long-term clinical follow-up. A
two-site time resolved ampliﬁed FRET method, detected by high
throughput mfFLIM, was exploited to assess the functional state of PKB/
Akt in these patients. Ef was utilised for determining the activation state
of PKB/Akt [4]. Some diﬀerences in ﬂuorescence lifetime occurred
between donor only samples when comparing primary and metastatic
samples; this is due to changes in the microenvironment between dif-
ferent tumours, such as pH and tissue type as metastatic tumours have
the capability of creating a new tumour microenvironment in a range of
tissue types. Comparisons between ﬂuorescence lifetimes are made
between donor and donor/acceptor samples of the same patient as these
are tissues of the same type and from the same tumour microenviron-
ment.
In summary, we have shown for the ﬁrst time that the activation
state of PKB/Akt in ccRCC patients, measured by A-FRET (but not by
IHC intensity) was correlated with poorer overall survival. This assay is
able to directly monitor the activation state of PKB/Akt in primary and
metastatic ccRCC tissue, and could be used to monitor posttranslational
modiﬁcations and complexes of other oncoproteins. The ability to ac-
curately quantify the functional state of oncoproteins has important
implications as a high number of ccRCCs, within their evolution, de-
velop distant lymphatic and/or haematogenous metastases [17],
whereby the prognostic impact of classical histologic features in the
primary tumour diminishes or disappears. Here prognostic models turn
to the prediction of response to systemic therapy [18]. Therefore, in
such a context, companion diagnostics such as A-FRET will prove va-
luable.
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